Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | TGF beta 1, 2 and 3 |
Clinical data | |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6392H9926N1698O2026S44 |
Molar mass | 144388.22 g·mol−1 |
(what is this?) (verify) |
Fresolimumab (GC1008) is a human monoclonal antibody [1] and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer [2] [3] ( kidney cancer and melanoma).
It binds to and inhibits all isoforms of the protein transforming growth factor beta (TGF-β). [2]
Fresolimumab was discovered by Cambridge Antibody Technology (CAT) scientists [4] and was one of a pair of candidate drugs that were identified for the treatment of the fatal condition scleroderma. CAT chose to co-develop the two drugs metelimumab (CAT-192) and fresolimumab with Genzyme. During early development, around 2004, CAT decided to drop development of metelimumab in favour of fresolimumab. [5]
In February 2011 Sanofi-Aventis agreed to buy Genzyme for US$20.1 billion. [6]
As of June 2011 [update] the drug was being tested in humans ( clinical trials) against IPF, renal disease, and cancer. [7] [8] On 13 August 2012, Genzyme applied to begin a Phase 2 clinical trial in primary focal segmental glomerulosclerosis [9] comparing fresolimumab versus placebo.
As of July 2014 [update], Sanofi-Aventis continue to list fresolimumab in their research and development portfolio under Phase II development. [10]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | TGF beta 1, 2 and 3 |
Clinical data | |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6392H9926N1698O2026S44 |
Molar mass | 144388.22 g·mol−1 |
(what is this?) (verify) |
Fresolimumab (GC1008) is a human monoclonal antibody [1] and an immunomodulator. It is intended for the treatment of idiopathic pulmonary fibrosis (IPF), focal segmental glomerulosclerosis, and cancer [2] [3] ( kidney cancer and melanoma).
It binds to and inhibits all isoforms of the protein transforming growth factor beta (TGF-β). [2]
Fresolimumab was discovered by Cambridge Antibody Technology (CAT) scientists [4] and was one of a pair of candidate drugs that were identified for the treatment of the fatal condition scleroderma. CAT chose to co-develop the two drugs metelimumab (CAT-192) and fresolimumab with Genzyme. During early development, around 2004, CAT decided to drop development of metelimumab in favour of fresolimumab. [5]
In February 2011 Sanofi-Aventis agreed to buy Genzyme for US$20.1 billion. [6]
As of June 2011 [update] the drug was being tested in humans ( clinical trials) against IPF, renal disease, and cancer. [7] [8] On 13 August 2012, Genzyme applied to begin a Phase 2 clinical trial in primary focal segmental glomerulosclerosis [9] comparing fresolimumab versus placebo.
As of July 2014 [update], Sanofi-Aventis continue to list fresolimumab in their research and development portfolio under Phase II development. [10]